# Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

> **NCT02324803** · PHASE2 · UNKNOWN · sponsor: **Southern China Urology Cancer Consortium** · enrollment: 86 (estimated)

## Conditions studied

- Self Efficacy
- Adverse Drug Event
- Carcinoma, Renal Cell

## Interventions

- **DRUG:** pazopanib

## Key facts

- **NCT ID:** NCT02324803
- **Lead sponsor:** Southern China Urology Cancer Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2014-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02324803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02324803, "Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02324803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*